---
title: "Nemtabrutinib Plus Venetoclax vs Venetoclax Plus Rituximab in Relapsed/Refractory CLL/SLL"
id: "clinicaltrials-nct05947851"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct05947851"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT05947851"
doi: "NCT05947851"
published_at: "2026-03-13T12:00:00.000Z"
evidence_level: "INTERVENTIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nemtabrutinib Plus Venetoclax vs Venetoclax Plus Rituximab in Relapsed/Refractory CLL/SLL
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct05947851
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT05947851)
- **DOI:** [NCT05947851](https://doi.org/NCT05947851)
- **Published At:** 2026-03-13T12:00:00.000Z
- **Evidence Rating:** INTERVENTIONAL Trial
## Executive GIST (TL;DR)
Official title: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) Summary: The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR). Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE3 Enrollment: 735 (ESTIMATED) Status: RECRUITING Completion: 2035-07-01 (ESTIMATED)
## Clinical Analysis & Structured Key Points
Study Intent and Design: - A Phase 3, open-label, randomized trial compares nemtabrutinib (MK-1026) plus venetoclax versus venetoclax plus rituximab in relapsed/refractory CLL/SLL following at least one prior therapy. - Primary aim is to evaluate progression-free survival (PFS) by 2018 iwCLL criteria, assessed via blinded independent central review (BICR). Population and Intervention: - Population: participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least one prior treatment. - Interventions: nemtabrutinib plus venetoclax versus venetoclax plus rituximab. Context and Outcomes: - The study seeks to assess safety and tolerability and to confirm the appropriate dose for the nemtabrutinib–venetoclax combination. - Primary hypothesis is that nemtabrutinib with venetoclax improves PFS compared with VR (venetoclax plus rituximab) per iwCLL criteria. Status and Scope: - Enrollment is estimated at 735 participants. - Status is Recruiting, with an anticipated completion date around July 1, 2035. Limitations: - Source does not provide numerical results, specific safety signals, or detailed secondary endpoints.
## Related Clinical Research

- [Low-dose vemurafenib plus rituximab (Scripps regimen) for frontline and relapsed hairy cell leukem](https://medichelpline.com/clinical-feed/pubmed-42308249.md) (DOI: 10.1182/bloodadvances.2025019243)
- [Pirtobrutinib sequencing in CLL: reasons for caution before first-line noncovalent BTK inhibition](https://medichelpline.com/clinical-feed/pubmed-42678527.md) (DOI: 10.1007/s00277-026-07264-x)
- [HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl.md)
- [One-month physicochemical stability of idarubicin diluted in polyolefin (Freeflex) infusion bags](https://medichelpline.com/clinical-feed/plos-one-21-one-month-physicochemical-stability-study-of-idarubicin-prepared-in-polyolefin.md)
- [MYC–MIZ1 Enhancer Complexes Regulate Neuroendocrine Identity in Small Cell Lung Cancer](https://medichelpline.com/clinical-feed/biorxiv-7-myc-miz1-complexes-at-enhancers-tune-neuroendocrine-identity-of-small-cell-lung.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.